Therapy Directory

Bispecific antibodies clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Bispecific antibodies as a study intervention. Browse Bispecific antibodies recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

362

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: AZD5863, AZD2936; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Jacksonville, Florida • Rochester, Minnesota • New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Fountain Valley, California • Fairfax, Virginia • Renton, Washington

Conditions: Non-Small-Cell Lung Cancer
Interventions: Amivantamab, Lazertinib, Carboplatin, Pemetrexed; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Orange, California + 14 more

Conditions: Hematological Malignancies
Interventions: Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more

Conditions: Hematological Malignancies
Interventions: Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 2 more

Conditions: Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions: NEOK002, NEOK002 RDE; Drug
Lead sponsor: NEOK Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Orlando, Florida • New York, New York • Nashville, Tennessee + 5 more

Conditions: Hematological Malignancies
Interventions: Teclistamab (IV), Teclistamab(SC); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 5
States / cities: Duarte, California • Denver, Colorado • New York, New York + 2 more

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 2 more

Conditions: Multiple Myeloma
Interventions: JNJ-79635322, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 42
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more

Conditions: Neoplasms, Advanced Solid Tumors
Interventions: JNJ-87890387; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Nashville, Tennessee

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions: Obinutuzumab, Glofitamab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

About this Bispecific antibodies clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Bispecific antibodies as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bispecific antibodies.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Bispecific antibodies clinical trials

Filter and sort this therapy

Live official records

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

A Study of JNJ-87890387 for Advanced Solid Tumors

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

About this Bispecific antibodies clinical trials directory page